Sonya Miller, MBBS, FFARCS, FANZCA, TauRx Therapeutics Ltd., Aberdeen, UK, discusses the recent double-blind, randomized, controlled Phase III LUCIDITY trial (NCT03446001) of the oral drug hydromethylthionine mesylate (HMTM; aka TRx0237). This global clinical trial enrolled patients from across the Alzheimer’s disease (AD) spectrum, assessing changes in Alzheimer’s Disease Assessment Scale–Cognitive (ADAS-Cog) and activities of daily living (ADL) scores as the primary endpoints. Data from the trial has demonstrated a sustained improvement in cognition in the MCI group and a reduction in the expected cognitive decline in the mild to moderate AD group, after 12 months of drug treatment. This has been further supported by a 93% reduction in change in neurofilament light chain (NfL) from baseline to 12 months, relative to controls. The group are currently beginning discussions with regulators in the UK, to bring this drug to patients with AD and frontotemporal dementia. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
